MIRM

Mirum Pharmaceuticals Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth↓ 2/10
  • Value↓ 0/10
Mirum Pharmaceuticals sales and earnings growth
MIRM Growth
Fair
  • Revenue Y/Y↑ 22.00%
  • EPS Y/Y↓ -745.34%
  • FCF Y/Y↓ -2092.81%
Mirum Pharmaceuticals gross and profit margin trends
MIRM Profitability
Neutral
  • Gross margin ↑ 81.40%
  • EPS margin↓ -140.20%
  • ROIC 5Y↓ -42.16%
Mirum Pharmaceuticals net debt vs free cash flow
MIRM Risk
Great
  • Debt / Equity↓ 1.3
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -54.3

Mirum Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks